Orasis Pharmaceuticals Announces FDA Approval of QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the Treatment of Presbyopia
QLOSI is expected to be commercially available in the U.S. in the first half of 2024.
- QLOSI is expected to be commercially available in the U.S. in the first half of 2024.
- "The FDA approval of QLOSI marks a tremendous milestone for Orasis as we continue our mission to provide a flexible treatment option for the millions of people in the U.S. living with presbyopia, or blurry near vision," said Elad Kedar, Chief Executive Officer of Orasis Pharmaceuticals.
- "I am grateful to the Orasis team, our strategic partners, clinical investigators, and patients who participated in our clinical trials, all of whom made this achievement possible."
- QLOSI (pronounced CLOH-see) is a prescription eye drop that can be used daily, or as needed, up to twice per day.